The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.
Eur J Med Chem
; 257: 115491, 2023 Sep 05.
Article
in English
| MEDLINE | ID: covidwho-2325420
ABSTRACT
The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (Mpro) of SARS-CoV-2 plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-19. Many SARS-CoV-2 Mpro inhibitors have been reported, including covalent and noncovalent inhibitors. The SARS-CoV-2 Mpro inhibitor PF-07321332 (Nirmatrelvir) designed by Pfizer has been put on the market. This paper briefly introduces the structural characteristics of SARS-CoV-2 Mpro and summarizes the research progress of SARS-CoV-2 Mpro inhibitors from the aspects of drug repurposing and drug design. These information will provide a basis for the drug development of treating the infection of SARS-CoV-2 and even other coronaviruses in the future.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Limits:
Humans
Language:
English
Journal:
Eur J Med Chem
Year:
2023
Document Type:
Article
Affiliation country:
J.ejmech.2023.115491
Similar
MEDLINE
...
LILACS
LIS